Garg Bhawandeep, Sharma Deepak, Bansal Anju
a Department of Neonatology , Surya Children's Medicare Pvt. Ltd , Mumbai , India.
b Department of Neonatology , National Institute of Medical and Sciences , Jaipur , India.
J Matern Fetal Neonatal Med. 2018 Dec;31(23):3214-3224. doi: 10.1080/14767058.2017.1366982. Epub 2017 Aug 23.
Hypoxic ischemic encephalopathy (HIE) is one of the leading causes of neonatal mortality in developing countries and leads to some form of neuro-developmental disability in latter part of life.
The aim of this study is to evaluate the role of erythropoietin (EPO) in neuroprotection for term newborn having HIE.
The literature search was done for various trials by searching the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, Web of science, Scopus, Index Copernicus, and other database.
A total of nine studies fulfilled inclusion criteria. EPO has shown to cause reduction in death and disability, better long-term neuro-developmental outcome, improvement in EEG, and reduction in risk of cerebral palsy.
EPO treatment has neuroprotective effects against moderate/severe HIE and improves long-term behavioral neurological developments in neonates.
缺氧缺血性脑病（HIE）是发展中国家新生儿死亡的主要原因之一，并会在生命后期导致某种形式的神经发育障碍。
本研究的目的是评估促红细胞生成素（EPO）在足月新生儿缺氧缺血性脑病神经保护中的作用。
通过检索Cochrane对照试验中心注册库（CENTRAL）、PubMed、EMBASE、科学网、Scopus、哥白尼索引及其他数据库，对各种试验进行文献检索。
共有9项研究符合纳入标准。促红细胞生成素已显示出可降低死亡和残疾率，带来更好的长期神经发育结局，改善脑电图，并降低脑瘫风险。
促红细胞生成素治疗对中度/重度缺氧缺血性脑病具有神经保护作用，并可改善新生儿的长期行为神经发育。
